BOSTON--(BUSINESS WIRE)--Intera Oncology® Inc., manufacturer of the only FDA-approved pump for Hepatic Artery Infusion (HAI) therapy for the treatment of intrahepatic cholangiocarcinoma (bile duct cancer confined to the liver) and colorectal cancer liver metastases, will showcase its Intera 3000 HAI pump as a sponsor of the 10th annual Cholangiocarcinoma Foundation Conference April 12 to 15 in Salt Lake City, Utah.
Intrahepatic cholangiocarcinoma (IHCC) has a very poor prognosis and patients treated with standard chemotherapy rarely survive beyond three years. The Intera 3000 HAI Pump delivers up to 400 times the concentration of medication to tumors in the liver compared to standard IV administration; and a meta-analysis of independent studies published in 2022 demonstrated a substantial increase in the survival of patients treated with HAI therapy along with systemic chemotherapy—with nearly 40% of patients still alive after three years.
“We are proud to sponsor the Cholangiocarcinoma Foundation Conference and fully support its efforts to bring awareness to this disease and improve survival and quality of life for patients,” said Intera Oncology President and CEO, Michael Gaisford. “Intera Oncology is passionate about ensuring anyone who can benefit from HAI therapy has access to it. By partnering with cancer centers and educating physicians, patients and caregivers, Intera Oncology is on a mission to change the course of cancer.”
Intera Oncology can be found on the exhibitor floor at booth #14, where experts will be available to educate event attendees about the importance of HAI therapy. Additionally, patient advocates like Rick Brookes, who was diagnosed at age 62 with bile duct cancer that had metastasized to his liver in 2015, will share personal stories at the event. “Doctors told me that my life was likely measured in weeks not months,” stated Brookes. “Today, I am back to my normal pre-cancer life. The HAI pump allowed me to resume my regular activities—without it, I would not be here today.”
The palm-sized Intera 3000 HAI Pump is implanted in the abdomen and designed to deliver a continuous flow of chemotherapy directly to the hepatic artery that feeds metastatic tumors in the liver. Individuals receiving HAI therapy continue their normal daily activities outside of a hospital with minimal disruption to their lives. Driven by patient demand and medical community support, the device has seen rapid physician adoption and is used to treat people with intrahepatic cholangiocarcinoma and colorectal cancer liver metastases in nearly 50 cancer centers across the U.S., including nine of the U.S. News & World Report’s top 10 in the nation.
To learn more about HAI therapy or Intera Oncology, visit www.InteraOncology.com. For more information about the Cholangiocarcinoma Foundation, visit cholangiocarcinoma.org.
ABOUT INTERA ONCOLOGY: Intera Oncology® Inc. is a Boston-based medical device company founded in 2019 by two doctors with a singular vision for improving the survival of colorectal cancer liver metastases and cholangiocarcinoma patients by ensuring access to Hepatic Artery Infusion (HAI) therapy. Dedicated to helping patients live longer and better lives by changing the course of cancer with HAI therapy, Intera Oncology manufactures the only FDA-approved pump for HAI therapy – the Intera 3000 Hepatic Artery Infusion Pump. Today, the treatment is used in nearly 50 cancer centers across the U.S., including nine of the U.S. News & World Report’s top 10 in the nation. Learn more at interaoncology.com and follow Intera on Twitter, LinkedIn and Facebook.
Editor’s Note: Patients and experts are available to share their HAI treatment stories. Contact intera@beyondfifteen.com or 949.733.8679 to schedule interviews.
